Norwegian doctor Gilbert, who had treated patients during the 1982 Israeli invasion of Beirut and later in Palestinian territories, speaks about his new mission
Pharmaceutical giant AstraZeneca on Thursday announced that clinical trials of an antibody-based Covid-19 drug had shown robust efficacy and long-term prevention.
The Anglo-Swedish laboratory follows in the footsteps of US firms Merck and Pfizer, which announced in October and early November respectively that they had developed drugs that could prevent severe forms of the disease, and that could be taken at the first sign of symptoms.
The AstraZeneca drug AZD7442, made from a combination of two antibodies, has been undergoing final stage clinical trials to assess its safety and efficacy.
A six-month follow-up trial “showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination”, it said in a statement.
ALSO READ:
One 300mg IM dose reduced the risk of developing symptomatic COVID-19 compared to placebo by 83 percent, it added.
More than 75 percent of participants had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, but no severe cases were recorded.
Another trial to test its efficacy in treating those already suffering from “mild to moderate” Covid symptoms showed that one 600mg IM dose reduced the risk of developing severe illness or death by 88 percent.
“These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives,” said Hugh Montgomery, professor of intensive care medicine at University College London.
“Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.”
AstraZeneca said the full results of both trials would be submitted for publication to a peer-reviewed medical journal.
It has already submitted an application to US regulators for approval of the drug to treat Covid-19.
AstraZeneca’s separate Covid vaccine, developed with the University of Oxford, helped enable Britain’s speedy Covid vaccination drive after it was approved in December 2020.
Norwegian doctor Gilbert, who had treated patients during the 1982 Israeli invasion of Beirut and later in Palestinian territories, speaks about his new mission
The Zadna Rating app will provide information about food establishments across 9,000 venues in the capital city
Competing at Japan's prestigious Taiheiyo Club in the Asia-Pacific Amateur Championship (AAC) has ignited the 17-year-old's determination for a breakthrough year ahead
Wait times can vary significantly based on the applicant's passport and the country from which they are applying
Lebanese Prime Minister Najib Mikati appealed to the international community to put pressure on Israel for a ceasefire
Generally, commission accounts for 2 per cent of the sale value and 5 per cent of the annual rental, excluding 5 per cent value-added tax
The Roads and Transport Authority offers multiple ways for motorists to pay their parking fees without having to do it physically
Year of war generates at least 42 million tonnes of rubble; UN estimate shows debris clearance might cost $1.2 billion; Piled up, rubble would fill Great Pyramid of Giza 11 times